Lipoxygenases in Atherosclerosis
Lipoxygenases in Atherosclerosis
批准号:
7193423
负责人:
GARRET A FITZGERALD
金额:
$33.81万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-12-01 至 2008-02-29
关键词:
Animal ModelAntisense RNAApolipoprotein EArachidonate 15-LipoxygenaseArachidonate 5-LipoxygenaseArterial Fatty StreakAtherosclerosisBone MarrowCandidate Disease GeneCellsCholesterol EstersChronicClinicalCytokine SignalingDataDevelopmentDiseaseDisease regressionDisruptionEnzymesEventExhibitsFaceFailureFoam CellsGene ExpressionGene SilencingGenesGeneticGoalsGrantHealth Care CostsHumanHydrogen PeroxideImmunohistochemistryIn VitroInflammationInflammatoryInstitutesInterleukin-12Knock-outKnockout MiceLasersLesionLeukotrienesLinkLipidsLipoxygenaseLymphocyteMediator of activation proteinMicroarray AnalysisModelingMolecular ProfilingMorbidity - disease rateMouse StrainsMusMyocardialNonesterified Fatty AcidsPathway interactionsPatternPeritoneal MacrophagesPopulationPredispositionProcessProteinsRoleSignal TransductionSmall Interfering RNASmooth Muscle MyocytesSocietiesStagingStrokeSusceptibility GeneTechniquesTherapeuticatherogenesiscell typecytokinefunctional outcomesin vivoin vivo Modelinsightlaser capture microdissectionmacrophagemortalitymouse modelreconstitutionresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Atherosclerosis is a chronic inflammatory disease of the vasculature that often progresses to debilitating or fatal myocardial and stroke events. Macrophages are key players in progression of this disorder, interacting with lymphocytes and smooth muscle cells. 12/15-Lipoxygenase (12/15-LO) and 5-Lipoxygenase (5-LO) are present in subpopulations of macrophages and can oxygenate accumulating lipids to form hydroperoxides and leukotrienes, which have a variety of potent pro-inflammatory actions. Data generated during the past cycle of this grant established strong evidence for a pro-atherogenic role of 12/15-LO in three distinct mouse models and provided initial insight into the mechanisms involved. Recent data from other labs have shown the presence of 5-LO in atherosclerotic lesions and implicated this gene as a major atherosclerosis susceptibility gene in mice. The overall goal of this proposal is to establish the role and mechanisms for lipoxygenases in atherosclerosis. A central hypothesis is that subpopulations of 12/15-LO and 5-LO expressing macrophages can contribute to atherogenesis via specific pro-inflammatory gene signaling networks. In Specific Aim 1, the expression and roles of 12/15-LO and 5-LO in atherosclerosis will be investigated. Considerable controversy now exists as to the true expression pattern of these enzymes throughout lesion development in humans and mice. We shall investigate expression patterns of 12/15-LO and 5-LO in atherosclerosis prone mice using immunohistochemistry and in specific macrophage populations using laser capture microdissecfion. The role of 5-LO in atherogenesis throughout the lifetime of mice on apoE and LDL-R genetic backgrounds will be examined by en face lesion analysis and potential additive or synergistic actions with 12/15-LO explored. Preliminary data in atherosclerotic models and microarray studies have indicated that lipoxygenase inhibition via gene disruption influences expression of several important cytokine and inflammatory mediators, which may offer an explanation for the roles of lipoxygenases in atherogenesis. In Specific Aim 2, we will employ a microarray approach to examine the alterations in gene expression in both 12/15-LO and 5-LO deficient macrophages compared to C57BL/6 wildtype controls. Candidate gene changes in expression will be verified and functional links to lipoxygenase/cytokine signaling explored. In Specific Aim 3, a small interfering RNA (siRNA) gene silencing approach will be instituted to block macrophage lipoxygenase expression. Overall, these studies will illuminate the importance of lipoxygenase pathways in macrophages in relation to atherosclerotic disease.
期刊论文(34)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1196/annals.1383.012
发表时间:
2006-01-01
期刊:
ABDOMINAL AORTIC ANEURYSM: GENETICS, PATHOPHYSIOLOGY AND MOLECULAR BIOLOGY
影响因子:
--
作者:
[Funk, Colin D., Cao, Richard Yang, Habenicht, Andreas J. R.]
通讯作者:
Habenicht, Andreas J. R.
DOI:
10.1074/jbc.271.39.24055
发表时间:
1996-09-27
期刊:
JOURNAL OF BIOLOGICAL CHEMISTRY
影响因子:
4.8
作者:
[Sun, DX, Funk, CD]
通讯作者:
Funk, CD
Role of 'platelet-type' 12-lipoxygenase in skin carcinogenesis.
“血小板型”12-脂氧合酶在皮肤癌发生中的作用。
DOI:
10.1016/s0304-3835(00)00634-0
发表时间:
2001
期刊:
Cancer letters
影响因子:
9.7
作者:
[Virmani,J, Johnson,EN, Klein-Szanto,AJ, Funk,CD]
通讯作者:
Funk,CD
DOI:
10.1161/atvbaha.108.162206
发表时间:
2008
期刊:
Arteriosclerosis, thrombosis, and vascular biology
影响因子:
--
作者:
[FitzGerald,GarretA]
通讯作者:
FitzGerald,GarretA
Cloning of a human "epidermal-type" 12-lipoxygenase-related gene and chromosomal localization to 17p13.
人类“表皮型”12-脂氧合酶相关基因的克隆和染色体定位至 17p13。
DOI:
10.1159/000014993
发表时间:
1998
期刊:
Cytogenetics and cell genetics
影响因子:
--
作者:
[Sun,D, Elsea,SH, Patel,PI, Funk,CD]
通讯作者:
Funk,CD
共 13 条
Institutional Clinical and Translational Sciences Award
-
批准号:10487653
-
项目类别:
-
资助金额:$6.13万
-
财政年份:2022
-
负责人:GARRET A FITZGERALD
-
依托单位:
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
-
批准号:10304145
-
项目类别:
-
资助金额:$65.41万
-
财政年份:2019
-
负责人:GARRET A FITZGERALD
-
依托单位:
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
-
批准号:10065018
-
项目类别:
-
资助金额:$66.99万
-
财政年份:2019
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:10348879
-
项目类别:
-
资助金额:$1016.45万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:9261656
-
项目类别:
-
资助金额:$998.54万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Phenotypic Diversity in COVID-19
-
批准号:10158887
-
项目类别:
-
资助金额:$63.39万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:10646280
-
项目类别:
-
资助金额:$1024.77万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:9562973
-
项目类别:
-
资助金额:$1000.41万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:10426378
-
项目类别:
-
资助金额:$1026.02万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:10227357
-
项目类别:
-
资助金额:$16.19万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Institutional Clinical and Translational Science Award
-
批准号:10455191
-
项目类别:
-
资助金额:$17.75万
-
财政年份:2016
-
负责人:GARRET A FITZGERALD
-
依托单位:
Personalization of Therapeutic Efficacy and Risk
-
批准号:8093372
-
项目类别:
-
资助金额:$373.63万
-
财政年份:2012
-
负责人:GARRET A FITZGERALD
-
依托单位:
Personalization of Therapeutic Efficacy and Risk
-
批准号:8689159
-
项目类别:
-
资助金额:$369.97万
-
财政年份:2012
-
负责人:GARRET A FITZGERALD
-
依托单位:
Personalization of Therapeutic Efficacy and Risk
-
批准号:8516094
-
项目类别:
-
资助金额:$372.04万
-
财政年份:2012
-
负责人:GARRET A FITZGERALD
-
依托单位:
Core A: Administrative
-
批准号:8126749
-
项目类别:
-
资助金额:$31.14万
-
财政年份:2012
-
负责人:GARRET A FITZGERALD
-
依托单位:
Personalization of Therapeutic Efficacy and Risk
-
批准号:9069494
-
项目类别:
-
资助金额:$366.61万
-
财政年份:2012
-
负责人:GARRET A FITZGERALD
-
依托单位:
CTSA INFRASTRUCTURE FOR PEDIATRIC CLINICAL TRIALS
-
批准号:8365016
-
项目类别:
-
资助金额:$249.44万
-
财政年份:2011
-
负责人:GARRET A FITZGERALD
-
依托单位:
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
-
批准号:8365017
-
项目类别:
-
资助金额:$78.55万
-
财政年份:2011
-
负责人:GARRET A FITZGERALD
-
依托单位:
CTSA INFRASTRUCTURE FOR AIDS RESEARCH
-
批准号:8365018
-
项目类别:
-
资助金额:$78.55万
-
财政年份:2011
-
负责人:GARRET A FITZGERALD
-
依托单位:
Animal Models and Drug Discovery
-
批准号:8205110
-
项目类别:
-
资助金额:$3.5万
-
财政年份:2011
-
负责人:GARRET A FITZGERALD
-
依托单位:
国内基金
海外基金
基于小鼠多组织和细胞链特异性RNA-seq数据的Antisense RNA分析及数据库构建
-
批准号:31271385
-
项目类别:面上项目
-
资助金额:95.0万元
-
批准年份:2012
-
负责人:胡松年
-
依托单位: